Qube Research & Technologies (QRT)
ENTA icon

Qube Research & Technologies (QRT)’s Enanta Pharmaceuticals ENTA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.14M Buy
162,000
+80,995
+100% +$1.08M ﹤0.01% 2290
2026
Q2 		$1.18M Sell
81,005
-35,956
-31% -$483K ﹤0.01% 2346
2026
Q1 		$1.48M Buy
116,961
+84,572
+261% +$1.13M ﹤0.01% 2324
2025
Q4 		$511K Buy
32,389
+20,469
+172% +$260K ﹤0.01% 2798
2025
Q3 		$143K Sell
11,920
-71,992
-86% -$575K ﹤0.01% 3003
2025
Q2 		$634K Sell
83,912
-3,955
-5% -$23.8K ﹤0.01% 2618
2025
Q1 		$485K Sell
87,867
-73,812
-46% -$456K ﹤0.01% 2556
2024
Q4 		$930K Buy
161,679
+40,660
+34% +$390K ﹤0.01% 2204
2024
Q3 		$1.25M Buy
121,019
+61,235
+102% +$801K ﹤0.01% 1949
2024
Q2 		$775K Sell
59,784
-42,841
-42% -$578K ﹤0.01% 1992
2024
Q1 		$1.79M Sell
102,625
-86,203
-46% -$1.14M ﹤0.01% 1824
2023
Q4 		$1.78M Buy
188,828
+75,156
+66% +$700K ﹤0.01% 1583
2023
Q3 		$1.27M Buy
113,672
+68,076
+149% +$1.1M ﹤0.01% 1612
2023
Q2 		$976K Buy
45,596
+29,942
+191% +$883K ﹤0.01% 1312
2023
Q1 		$633K Sell
15,654
-7,742
-33% -$370K ﹤0.01% 1473
2022
Q4 		$1.09M Sell
23,396
-11,303
-33% -$515K 0.01% 1190
2022
Q3 		$1.8M Buy
34,699
+29,414
+557% +$1.72M 0.01% 972
2022
Q2 		$250K Sell
5,285
-4,018
-43% -$218K ﹤0.01% 1638
2022
Q1 		$662K Buy
9,303
+824
+10% +$53.6K 0.01% 1391
2021
Q4 		$634K Buy
+8,479
New +$665K ﹤0.01% 1450
2020
Q1 		– Sell
-8,096
Closed -$500K – 1263
2019
Q4 		$500K Buy
+8,096
New +$502K 0.02% 950

Other funds holding ENTA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Hillsdale Investment Management
Hillsdale Investment Management Toronto, Ontario, Canada $4.42B AUM 54.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ENTA Position: Q3 2026 in Review

Qube Research & Technologies (QRT) increased its Enanta Pharmaceuticals (ENTA) stake by 100% in Q3 2026, buying an estimated $1.08M and bringing the position to 162,000 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

Qube Research & Technologies (QRT) first reported a position in ENTA in Q4 2019 and has held it in 21 quarters since. 86 funds tracked by Wall St. Rank hold ENTA as of Q3 2026.

  • Qube Research & Technologies (QRT) held 162,000 shares of Enanta Pharmaceuticals worth $2.14M as of Q3 2026.
  • Qube Research & Technologies (QRT) bought 80,995 Enanta Pharmaceuticals shares in Q3 2026, an estimated $1.08M.
  • Enanta Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #2290 holding.
  • Qube Research & Technologies (QRT) first reported a position in Enanta Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
  • 86 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.